Dana Feuerhammer
Medical · Marlton, NJNPI 1982117438
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.9%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 73.9% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $6,601, more than ten times the $520 reported in 2021. Among medical clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $47.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- SK Life Science, Inc.$409
- Bristol Myers Squibb$303
- UCB, Inc.$199
- Lundbeck LLC$142
- E.r. Squibb & Sons, L.L.C.$137
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$5,44456%
- Food & beverage$4,29744%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 99 | $7,196 |
| SK Life Science, Inc. | 17 | $409 |
| Bristol Myers Squibb | 13 | $303 |
| UCB, Inc. | 12 | $199 |
| Lundbeck LLC | 3 | $142 |
| E.r. Squibb & Sons, L.L.C. | 2 | $137 |
| W. L. Gore & Associates, Inc. | 2 | $137 |
| Impel Pharmaceuticals Inc. | 2 | $126 |
| Silk Road Medical, Inc. | 1 | $123 |
| Lilly USA, LLC | 7 | $118 |
| Novartis | 7 | $114 |
| Biogen | 6 | $106 |
| Genentech USA, Inc. | 4 | $90 |
| AstraZeneca | 5 | $84 |
| Boston Scientific | 3 | $76 |
| Pfizer | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Amgen | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Johnson & Johnson | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Impel Pharmaceuticals LLC | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Argenx US, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Aucta Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$5,283
- QULIPTA$1,472
- ZEPOSIA$247
- XCOPRI$125
- ENROUTE Transcarotid Stent$123
- ENROUTE Transcarotid Neuroprotection System$123
- GORE CARDIOFORM Septal Occluder$122
- VYEPTI$103
- Trudhesa$101
How this compares
$9,743 in reported general payments places this provider in the 95th percentile of 573 medical providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 73 | $105,786 |
| AustedoDeutetrabenazine | 12 | $64,835 |
| BotoxOnabotulinumtoxina | 25 | $33,695 |
| Emgality PenGalcanezumab-Gnlm | 43 | $29,081 |
| Nurtec OdtRimegepant Sulfate | 24 | $27,658 |
| QuliptaAtogepant | 19 | $21,479 |
| Carbamazepine ErCarbamazepine | 46 | $5,142 |
| Levetiracetam | 109 | $5,054 |
| Memantine Hcl | 116 | $3,979 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 16 | $2,721 |
| Gabapentin | 131 | $2,587 |
| Oxcarbazepine | 57 | $2,418 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 48 | $2,413 |
| Divalproex Sodium | 20 | $2,369 |
| Donepezil Hcl | 41 | $1,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Qulipta | $7,196 | $160,961117 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $25 | $64,83512 claims |
| PfizerNurtec Odt | $54 | $27,65824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 medical providers in New Jersey.
Other medical in Marlton
- Stephanie PhillipsMarlton$12K
- Christine PriestMarlton$7K
- Shannon WelnerVerona$176K
- Christinna DelgenioColts Neck$114K
- Anita FoxVerona$17K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Gabriela Plesek-AndiaVerona$13K
- Sean AdairCape May Court House$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.